Envision Pharma Group announces appointment of Dr. Deepti Sodhi Jaggi to Board of Directors

Envision Pharma Group (Envision) has appointed Dr. Deepti Sodhi Jaggi to the Envision Board of Directors

“We are pleased to welcome Deepti to the Envision Board of Directors,” shares Meg Heim, CEO of Envision Pharma Group. “Deepti’s deep experience in the technology of Artificial Intelligence (AI) and digital therapeutics in the life sciences industry will be invaluable to our mission at Envision as we continue to accelerate our global business expansion and commitment to our clients, and most importantly, impacting patient lives in a positive manner.” 

Dr. Jaggi’s career includes over 20 years of experience in driving innovation at the intersection of life sciences, healthcare, and technology. Her expertise is in transforming businesses through software, AI/ML, and advanced analytics. Most recently, she served as Chief Strategy & Commercial Officer at Better Therapeutics, a publicly held digital therapeutics company. Before that, she served as the Global Head of Patient Insights & Solutions at Astellas Pharmaceuticals with responsibility for the Americas, EMEA, China, and Japan.

Prior to that, Dr. Jaggi served as President & Chief Medical Officer at Clinakos Inc., a Silicon Valley company at the forefront of leveraging data and AI in healthcare and life sciences. She helped grow Clinakos from startup to revenue stage, serving multiple top pharmaceutical companies.

Dr. Jaggi’s previous experience includes positions of increasing responsibility and leadership at Johnson & Johnson, Genentech, Oracle, and Kaiser Permanente. She has also served as a consultant to TPG Capital and is a member of the Board of Directors for Technology Credit Union in the San Francisco Bay Area.

“I am thrilled to join the Envision Board at such an exciting time for our industry. I look forward to working with an immensely talented team to accelerate innovation in life sciences through technology and scientific solutions to positively impact patient lives,” says Dr. Jaggi. 

Dr. Jaggi’s educational background includes a PharmD from the University of Southern California and an MBA from Stanford Graduate School of Business. 

Close

Dr Joseph Kohles will assume the position of Chief Medical Officer (CMO) to provide medical leadership across the group, provide direction for the development of medical strategy for our clients, provide a peer-to-peer contact for our Medical Affairs clients, and aid in the development/optimization of new technology solutions to support our expanding range of Medical Affairs services. Joe will also head-up a Medical Strategy “think tank” within Envision to provide our clients with leading-edge solutions to the changing demands of the Medical Affairs team and the environment in which they operate.

David Thompson will assume the position of Chief Strategy Officer (CSO) to help drive Envision's continued growth into the leading, global Medical Affairs agency, incorporating expanded multichannel medical communications capabilities, and oversee our expansion into appropriate global locations to facilitate closer proximity to our client base. David will also ensure the continued and improved synergy between our scientific services and supporting technology solutions to maintain Envision’s position as the only medical communications company that encompasses world-class scientific expertise, supported by industry-leading technology solutions to compliantly deliver multichannel medical communication programs. Although responsible for ensuring effective delivery of our scientific services across all 10 of our current global offices, David will be relocating to the UK as part of his new role, and will be based out of our Horsham office for alignment with the existing operational leadership team.

The current leadership team Brian Hepburn (CEO), Greg Caswill (Chairman), Joe Brown (President of Envision Technology Solutions) and John Gillie (CFO) will remain in their existing positions and welcome the augmented structure of leadership team as Envision continue their expansion.

Brian Hepburn, commented, “David and Joe bring incremental strength and depth to the management team, further extending our capabilities and expertise and enhancing our objective of becoming the comprehensive strategic partner to the Medical Affairs departments of our extensive client base.”

Envision Pharma Group are still recruiting for open positions at all levels across the organization – https://www.envisionpharmagroup.com/careers.

For an informal discussion, or to apply for any of these roles, please contact Karen Kent (Envision Pharma Group Recruiter – Karen.Kent@EnvisionPharmaGroup.com).

About Envision

Founded in 2001, Envision Pharma Group is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology, and medical device companies. Initially focusing on re-inventing the way biopharma companies managed their global data communications programs through the use of smart technology and best-in-class publication planning; Envision has evolved to become a leading provider of evidence communication services and Medical Affairs solutions encompassing all aspects of scientifically-driven data dissemination activities required to support a successful access to market strategy for new biopharma compounds.

This capability of the organization is further enhanced with industry-leading, complementary technology solutions across the Medical Affairs responsibilities. Envision has grown steadily under consistent leadership across its three core business areas in support of the Medical Affairs team that include (i) Evidence Communication – including strategic publication planning, data dissemination services, medical education, and Market Access communications; (ii) Technology Solutions – design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including, publication planning and management (Datavision®), clearance approval (Clear®), activity request management (Visiontracker®), workflow management for HEOR activities (Visiontracker HEORTM), searchable repository for the sharing of appropriate educational and training materials (LibraryTM), and next generation solution for managing medical information enquiries (MedinfoTM); (iii) Consulting Solutions – policy, process, compliance, and guideline consultancy to life-science companies.

Envision currently has ten offices, three in the United Kingdom – Horsham, Wilmslow, and London; five in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT; and two in Asia Pacific – Tokyo and Sydney. The company employs approximately 450 team members, including over 185 highly qualified and experienced in-house medical writers and a more than 80-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 18 of the top 20 pharmaceutical companies.

Close

Operating globally, Envision is a recognized partner to the Medical Affairs organizations providing scientific data communication services and industry-leading technology solutions to biopharmaceutical and medical devices companies on a global basis. Envision assists its clients in supporting the commercialization of new compounds via strategic data-communication planning, medical writing, medical communications services, and providing best-in-class technology solutions across the key operational functions of Medical Affairs.

Since inception in 2001, Envision has enjoyed strong year-on-year organic growth of c.20%. In addition to this organic growth, Envision has recently made two strategic acquisitions: ProScribe − extending their global reach into the Asia-Pacific region; and the Alligent Group − expanding their range of medical communication services to fully support their data continuum strategy across Medical Affairs functions. Envision has also launched several new solutions, including: Medical Information, HEOR Portfolio Management, and the Medical Affairs Library, which enhance the suite of solutions focused on Medical Affairs operational excellence.

These acquisitions and solution expansions further bolster Envision’s capabilities and build upon the range of service and solution offerings, which, in addition to publication planning and delivery, have grown to encompass medical strategy consultancy, Market Access communications, medical communications & MSL support, digital and creative services, and policy and operational excellence consultancy.

Envision’s unique position within the growing market of outsourced Medical Affairs services is underpinned by seamlessly marrying unparalleled scientific and industry expertise with a range of purpose-built, technology solutions that facilitate knowledge-sharing, operational excellence and decision-making effectiveness.

Datavision® is the industry standard solution for compliant publication planning, execution and management. However, the range of innovative and strategic management software, purpose-built for life-science clients has also expanded to provide support for our newer service offerings in Medical Affairs and Market Access:

• Library™ – Efficient access management of approved for use scientific materials across the enterprise. Provides easy sharing and multi-faceted search capabilities, notifies users of new material for release, expiration of material, and when new content becomes available based on a user’s profile.
• Visiontracker® – The industry-leading, web-enabled software application to manage all global independent investigator trial (clinical, non-clinical, and collaborations), medical education, and charity programs.
• Medinfo™ – The complete, next-generation global medical information solution that will change the way your company shares information and gathers insights.
• Clear® – A purpose-built solution to facilitate the compliant, efficient, and appropriate evaluation of all scientific materials targeted for disclosure.
• Visiontracker HEOR™ – The complete workflow solution to manage your HEOR project portfolio including project evaluation and approval, vendor management, HQ and country transparency, and financial management.

In line with our goal to facilitate efficient knowledge-sharing, operational excellence, and decision-making capabilities across Medical Affairs and executives in global life-science organizations, we are launching the new iEnvisionTM Medical Affairs platform. The primary objective of iEnvisionTM is to provide a suite of purpose-built solutions to facilitate/support industry best practice within the Medical Affairs organization. The iEnvisionTM suite enables effective communication and monitoring of the plans, consistency for reporting and KPI metrics, and establishes consistent and auditable controls for compliance purposes. Our new Library™ and Medinfo™ solutions are available now, and our existing classic solutions are being moved to the platform during 2016 (Visiontracker®) and 2017 (Datavision® and Clear®), with additional complementary solutions already being designed.

Regarding the importance of the iEnvisionTM platform, Joseph Brown, President of ETS, said “The iEnvisionTM platform and modules, through collaboration with our client partners, is a cornerstone to help support the future Medical Affairs operational model. iEnvisionTM will enhance a Medical Affairs team’s efficiency and quality, improve global effectiveness and alignment by connecting HQ and country operations, reduce costs by improving global scalability and facilitating the concept of a Medical Affairs center of excellence, and improve overall decision-making by creating a ‘data forward’ line of sight across Medical Affairs. The partnership with Ardian and GHO enables us to enhance our already significant investment in the platform in terms of both transitioning our existing solutions to iEnvisionTM and bringing additional new solutions, purpose-built to support Medical Affairs business needs, to market in a timely and efficient manner.”

Brian Hepburn, CEO of Envision, said “This partnership with Ardian and GHO Capital provides the resources, expertise, and market knowledge for Envision to realize the next stage of its development and become the leading solution provider to the Medical Affairs departments within the biopharmaceutical industry. We are uniquely positioned to support our clients via our in-depth, strategically focused, scientific communication capabilities in combination with our expanding range of technology solutions that support compliant and transparent communication of scientific evidence. With the support of Ardian and GHO Capital, we will continue to invest in these core competencies and further extend the market reach of our enterprise technology platform, iEnvisionTM.”

Simon Cottle, Managing Director of Ardian Mid Cap Buyout in London, said “After analyzing the outsourced Medical Affairs services and software market, we identified Envision as having the highest potential for further growth. Their management team has done a great job in creating a market-leading proposition and we look forward to working with them in the next stage of the business’ development.”

Bruno Ladriere, Managing Director of Ardian Mid Cap Buyout in London, added “We believe that Ardian’s transparent management-centric culture, coupled with our global ability to support development through organic and external growth, were the key elements in winning the support of Envision’s management and executing this acquisition.”

Mark Branganza, Partner at GHO Capital, added “Envision is a high growth company operating in the attractive healthcare outsourced services sub-sector with a strong platform and an international, blue-chip customer base. The opportunity to partner with Ardian and the management team, allowing us to pool our significant expertise in consulting and healthcare IT, was therefore extremely compelling for our fund. We look forward to our partnership in supporting the next phase of Envision’s continued growth.”

About Envision

Founded in 2001, Envision Pharma is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology, and medical device companies. Initially focusing on re-inventing the way biopharma companies managed their global data communications programs through the use of smart technology and best-in-class publication planning; Envision has evolved to become a leading provider of evidence communication services and Medical Affairs solutions encompassing all aspects of scientifically driven data dissemination activities required to support a successful access to market strategy for new biopharma compounds.

This capability of the organization is further enhanced with industry-leading, complementary technology solutions across the Medical Affairs responsibilities. Envision has grown steadily under consistent leadership across its three core business areas in support of the Medical Affairs team that include (i) Evidence Communication – including strategic publication planning, data dissemination services, medical education, and Market Access communications; (ii) Technology Solutions – design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including, publication planning and management (Datavision®), clearance approval (Clear®), activity request management (Visiontracker®), workflow management for HEOR activities (Visiontracker HEORTM), searchable repository for the sharing of appropriate educational and training materials (LibraryTM), and next generation solution for managing medical information enquiries (MedinfoTM); (iii) Consulting Solutions – policy, process, compliance, and guideline consultancy to life-science companies.

Envision currently has ten offices, three in the United Kingdom – Horsham, Wilmslow, and London; five in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT; and two in Asia Pacific – Tokyo and Sydney. The company employs approximately 450 team members, including over 185 highly qualified and experienced in-house medical writers and a more than 80-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 18 of the top 20 pharmaceutical companies.

About Ardian

Ardian, founded in 1996 and led by Dominique Senequier, is an independent private investment company with assets of US$55bn managed or advised in Europe, North America, or Asia. The company, which is majority-owned by its employees, keeps entrepreneurship at its heart and delivers investment performance to its global investors while fuelling growth in economies across the world. Ardian’s investment process embodies three values: excellence, loyalty, and entrepreneurship.
Ardian maintains a truly global network, with more than 410 employees working through twelve offices in Paris, London, Frankfurt, Milan, Madrid, Zurich, New York, San Francisco, Beijing, Singapore, Jersey, and Luxembourg. The company offers its 470 investors a diversified choice of funds covering the full range of asset classes through Ardian Direct Funds (comprising Ardian Mid Cap Buyout, Ardian Expansion, Ardian Growth, and Ardian Co-Investment), Ardian Infrastructure, Ardian Funds of Funds (comprising primary, early secondary, and secondary activities), Ardian Private Debt, Ardian Real Estate, and customized mandate investment solutions with Ardian Mandates.

About GHO Capital

Global Healthcare Opportunities, or GHO Capital Partners LLP, was founded in 2014 as a specialist healthcare investment adviser based in London. Its vision is to apply global capabilities and perspectives to build a world-class healthcare specialist private equity firm by recognising and seizing the highly attractive and underpenetrated European market opportunity. GHO Capital has a powerful combination of transaction, investment, and industry skills which sets it apart from traditional private equity firms. For further information please visit www.ghocapital.com.

Close

Anne Clare joins the Envision management team that oversees operations in Wilmslow, and across our nine other offices in the UK, US, and Asia-Pacific. As part of our continued expansion, Wilmslow, will serve as a North West office for the expansion of Envision’s core services and will also act as a head office for the Alligent Group’s (“Alligent”) European operations. Alligent, a leading Medical Affairs agency that develops and delivers strategically focused, integrated and aligned medical communications solutions to the biopharma industry, became part of the Envision Pharma Group in September, 2015.

Envision’s CEO, Brian Hepburn, commented, “The new office in Wilmslow not only provides a base for Alligent’s European operations, but continues Envision’s structured expansion with an office in the North West of England, a traditional centre of excellence for medical communications. The new location, coupled with Anne Clare’s leadership capabilities and client-centric approach, will help drive the continued expansion of Envision’s service line capabilities while establishing Alligent’s European operations as this business unit continues to thrive.”

Alligent Group founders, David Thompson and Joe Kohles, added, “We are delighted to open our Wilmslow office with such a well-recognized and vastly experienced medical communications leader in Anne Clare. Under her stewardship we are confident Envision’s North West footprint will grow rapidly as a centre of excellence for the industry’s brightest talent as well as serve as a commercial hub for Alligent's thriving European medical strategy business.”

The Envision Pharma Group, including the Alligent European team, are still recruiting for open positions at the level of Scientific Director, Medical Writer (all levels), Account Manager and Account Director.

For an informal discussion, or to apply for any of these roles, please contact Karen Kent (Envision Pharma Group Recruiter – Karen.Kent@EnvisionPharmaGroup.com) or Anne Clare Wadsworth (Head of Alligent Europe − Anne-Clare.Wadsworth@EnvisionPharmaGroup.com).

About Envision

Founded in 2001, Envision Pharma Group is an international, innovative, global technology and scientific communication company serving the medical affairs requirements of pharmaceutical, biotechnology, and medical device companies. Initially focusing on publication planning, Envision has evolved to become a leading provider of evidence-based communication services, encompassing all aspects of scientifically driven data dissemination activities required to support a successful “access to market strategy” for new biopharma products.

This capability of the organization is further enhanced with industry-leading, complementary technology solutions. Envision has grown steadily under consistent leadership across its three core business areas in support of the Medical Affairs Team that include (i) Evidence Communication – including strategic publication planning, data dissemination services, Med Ed and market access communications; (ii) Technology Solutions – design, development, implementation, and support of innovative and strategic management software purpose-built for life-science clients including publication planning and management (Datavision®), clearance approval (Clear®), activity request management (Visiontracker®), workflow management for HEOR activities (Visiontracker HEORTM), searchable repository for the sharing of appropriate educational and training materials (LibraryTM), and next generation solution for managing medical enquiries (MedinfoTM); (iii) Consulting Solutions – policy, process, compliance, and guideline consultancy to life-science companies.

Envision currently has ten offices, three in the United Kingdom – Horsham, Wilmslow and London; five in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT; and two in Asia-Pacific – Tokyo and Sydney. The company employs approximately 460 team members, including over 185 highly qualified and experienced in-house medical writers and a more than 70-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 18 of the top 20 pharmaceutical companies.

About the Alligent Group

Alligent was acquired by the Envision Pharma Group in September, 2015. Alligent was built to support the strategic and tactical needs of our clients’ medical directors and currently provides strategic medical planning and program implementation for the Medical Affairs Departments of a number of leading biopharma organizations. Based in Stirling, NJ, the company employs over 50 communications and scientific experts with extensive industry and agency experience, particularly within the area of oncology.

Close

Alligent’s core skill sets of medical strategy development and planning, allied program implementation and stakeholder support will complement Envision’s existing services of strategic data dissemination – including publication planning, consultancy, and market access communications – to provide global Medical Affairs Departments with compliant, strategically focused evidence communication programs. Underpinning its services, the expanded Envision Pharma Group will continue to provide its expansive client base with industry leading technology including Datavision®, Visiontracker®, Clear™ and Medinfo™. Alligent’s two principals, Joe Kohles and David Thompson, will also be joining the Envision Pharma Leadership team.

Envision's CEO, Brian Hepburn, commented, "The addition of Alligent to the Envision Pharma Group further cements our core tenet of becoming the leading international medical affairs agency. By acquiring Alligent, we are able to expand the capabilities we offer to medical affairs teams to ensure optimal evidence communication and ultimate product adoption based on scientific rigor.”

Messrs. Kohles and Thompson stated, “We are delighted to join the Envision Pharma Group. Our focus on medical strategy, coupled with Envision’s global presence and technology leadership position, offers the potential for us to expand and enrich our service breadth and offering to current and future clients alike. We look forward to joining the Group’s leadership team and contributing to the continued success of both Alligent and Envision.”

“The addition of the Alligent team is truly complimentary to the Envision Pharma group. We believe their combined capabilities will further enhance Envision’s ability to optimize the communication of complex scientific data on behalf of their clients, which will be of ultimate benefit to health care providers, payors and patients," added Halifax principal Scott Plumridge.

About Envision

Founded in 2001, Envision Pharma is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology and medical device companies. Initially focusing on publication planning Envision has evolved to become a leading provider of evidence communication services encompassing all aspects of scientifically driven data dissemination activities required to support a successful access to market strategy for new biopharma compounds.

This capability of the organization is further enhanced with industry leading complementary technology solutions. Envision has grown steadily under consistent leadership across its three core business areas that include (i) Evidence Communication – including strategic publication planning, data dissemination services and market access communications; (ii) Technology Solutions - design, development, implementation and support of innovative and strategic management software for life sciences clients including publication planning and management (Datavision®), clearance approval (ClearTM), and activity request management (Visiontracker®); and (iii) Consulting Solutions – policy, process, compliance and guideline consultancy to life-science companies.

Envision has eight offices, two in the United Kingdom - Horsham and London, four in the United States including offices in Philadelphia, PA; Southport, CT; Madison, NJ and Glastonbury, CT and two in Asia Pacific -Tokyo and Sydney . The company employs approximately 380 team members, including over 160 highly qualified and experienced in-house medical writers and a 65-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 19 of the top 20 pharmaceutical companies.

About the Alligent Group

Alligent was built to support the strategic and tactical needs of the medical director and currently provides strategic medical planning and program implementation for the medical affairs departments of a number of leading biopharma organizations. Based in Stirling, NJ, the company employs over 30 communications and scientific experts with extensive industry and agency experience, particularly within the area of oncology.

About The Halifax Group

The Halifax Group is a private equity firm that partners with managers and entrepreneurs to recapitalize and grow lower middle-market businesses across a variety of industries including health and wellness, infrastructure, business and government services, and franchising. The firm maintains offices in Washington, D.C.; Dallas, TX; and Raleigh, NC. For more information, please visit www.thehalifaxgroup.com.

Contact:
Caroline Luz
Owen Blicksilver Public Relations, Inc.
203-656-2829
caroline@blicksilverpr.com

Close

ARC’s focus is on young investigators and programs that will assist these investigators in achieving success in their academic research career. The “Young Investigators’ Forum” (YIF) is ARC’s flagship program. YIF programs are non-commercial scientific research forums directed at young investigators with a goal of stimulating development of careers in academic research, a crucial area for improving patient management and outcomes.

Young investigators submit an abstract of their research based on specified criteria to a panel of expert faculty in a specific therapeutic area who then evaluate the research. The authors of the top research are selected to attend the YIF, where they present their research in full and the same expert faculty comment, question, give feedback and make suggestions to the young investigators on the research presented. The top presenters are awarded a grant to be used for their research. In addition, expert faculty provide career advice and experience-based presentations on selecting a mentor, acquiring grants, publishing research, achieving balance between work and family, and related topics. The support for all researchers and faculty to attend the YIF is provided through educational grants. Programs can be accredited for continuing medical education through Joint Providership Policies and Agreements with our educational partners. All accredited YIF activities are planned and implemented in accordance with the Accreditation Council for Continuing Medical Education (ACCME®) Essential Areas and policies as well as current reporting requirements.

Of note, many of the young investigators who are now recognized leaders in academic research positions have credited their career success in part to this learning experience.

For more information on ARC, please contact:

John A. Romankiewicz, Pharm D
Director, Young Investigator Programs
ARCoalition LLC
333 Main Street
Madison, NJ 07940
Tel: 973-443-3829
Email: John.Romankiewicz@ar-coalition.com
http://www.ar-coalition.com

Close

To augment the acquisition of ProScribe made earlier in the year, Envision has established a new office in a prime location in Sydney, Australia. Commenting on the investment, Brian Hepburn, CEO said, “We are delighted to have made this strategic investment in the area, increasing our service capabilities with a new office in close proximity to a number of our key clients”.

Envision Pharma Group has employees in multiple offices in Europe, North America and the Asia-Pacific region. On Envision’s continued expansion, Brian noted that “With a strong history of unique and innovative publication and technology capabilities and our recent evolution into additional medical communications solutions, Envision Pharma Group is busier than ever. All our offices are growing as we continue to strengthen our support to more than 60 life sciences companies”.

Envision Pharma Group is seeing the growth in publication and overall medical communication programs matched by an increase in technology solutions, which now have over 120,000 individual users. Hepburn explained that, “the Group will continue to look to expand further, with other global offices likely to be established during the next 18 months”. Located in the Macquarie Park area of Northern Sydney, the office is approximately 12 km from Sydney’s central business district. Dr Mark Woolley, who heads up the new location said, “This presence further cements our Asia-Pacific capabilities and establishes us in a well recognised location within the region, with close proximity to a number of our key clients”.

ProScribe – Envision Pharma Group is located at:
Suite 1.01
Talavera Business Park
Level 1, 6‒10 Talavera Rd
Macquarie Park, NSW 2113
Australia
Tel: + 61 2 8058 4350
Fax: +61 2 8058 4352
For further information, please email either:
Alex Torre-Tasso: Alex.Torre-Tasso@EnvisionPharmaGroup.com
or
Karen Woolley: karen.woolley@EnvisionPharmaGroup.com.

Close